Medicine for preventing ischemic diseases

A preventive medicine, ischemic technology, applied in cardiovascular system diseases, metabolic diseases, drug combinations, etc., can solve the problem of not knowing the protective effect and so on

Inactive Publication Date: 2016-11-09
JX NIPPON OIL & ENERGY CORP
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, it is not known that carotenoids such as astaxanthin have a protective effect on ocular ischemic syndromes such as ischemic retinal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for preventing ischemic diseases
  • Medicine for preventing ischemic diseases
  • Medicine for preventing ischemic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] [Example 1] Measurement of electroretinogram [ERG]

[0054] An electroretinogram is a potential obtained by collecting electrical activity in the sensory retinal layer and retinal pigment epithelium layer generated by light stimulation from a wide range of the fundus of the eye. The a wave is a negative potential change in the cornea that occurs within a latency of 1.5 msec after flash stimulation of the eyeball, and it can be considered to be a potential originating from the surface layer of the retina (visual cell layer). Clinically, the abnormalities of a wave are ophthalmic artery occlusion and retinal detachment. The b wave is a large corneal positive potential change after the a wave, which can be considered to be the potential originating from the Muller tissue (from the middle layer to the inner layer) of the retina. Clinically, if the amplitude of b-wave is small, it is suspected to be central retinal artery occlusion, congenital retinoschisis, and congenital sta...

Embodiment 2

[0056] [Example 2] Histological evaluation of retina

[0057] After the electroretinogram measurement, a paraffin section of the eyeball was made, and histological evaluation was performed by hematoxylin-eosin staining.

[0058] In this embodiment, such as image 3 As shown, the retina of the ocular ischemic syndrome model mouse that took astaxanthin for health food showed the same normal structure as the unligated mouse, but the ocular ischemia syndrome model that only took the solvent (olive oil) The mouse's retina is structurally disordered.

[0059] When the number of cells in the ganglion cell layer (GCL) of the retina is compared, the number of cells in the group taking astaxanthin for health food is significantly higher than that in the group taking only the solvent, which is the same as that of the unligated group.

[0060] In addition, when comparing the thickness of the inner reticulum layer (IPL) and the inner granular layer (INL), the group that took astaxanthin for health...

Embodiment 3

[0071] [Example 3] Cell protection effect under OGD stress

[0072] Nuclear staining means that only dead cells are stained (PI-positive cells).

[0073] Such as Figure 5 As shown, the number of dead cells in RGC-5 cells supplemented with astaxanthin for health food is significantly less than that of RGC-5 cells supplemented with solvent (DMSO). When 10μM astaxanthin for health food is added, there is a drug-dependent effect. Daravone has the same degree of cell protection.

[0074] When OGD stress was not applied, there was no cell death caused by astaxanthin and edaravone used in health foods.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the present invention is to provide a prophylactic agent for retinal disorders including ischemic retinal disorders. The present invention specifically relates to a prophylactic agent for retinal disorders, which contains, as an active ingredient, a carotenoid mixture containing astaxanthin as the main component.

Description

Technical field [0001] The present invention relates to, for example, a drug for preventing retinal disorders containing carotenoids. Background technique [0002] In recent years, with the increase of lifestyle diseases, atherosclerosis due to arterial hypertrophy has increased. Atherosclerosis is believed to be caused by risk factors such as hyperlipidemia, diabetes, high blood pressure, and smoking. Atherosclerosis occurs inside the arteries, causing occlusion or stenosis of the blood vessels. The transport of oxygen or nutrients is stopped due to vascular occlusion, causing stroke, cerebral thrombosis, subarachnoid hemorrhage, myocardial infarction, transient amaurosis, etc. Due to stenosis or temporary occlusion of blood vessels, blood supply is stagnant, causing cerebral ischemia, angina pectoris, ocular ischemia syndrome, etc. [0003] Therefore, people have always wanted to prevent various diseases caused by arteriosclerosis. [0004] At the same time, it is known that car...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A23L33/10A23L2/52A61K35/74A61P27/02A61P27/06
CPCA61K35/74A61K45/06A23L33/10A23L33/105A23L33/155A61K31/122A61P27/02A61P27/06A61P9/10A61P9/12A61P3/10A61K2300/00A23L33/135A23V2002/00A23V2200/30
Inventor 原英彰石桥卓
Owner JX NIPPON OIL & ENERGY CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap